OR WAIT null SECS
TWIN FALLS, Idaho -- Medical Discoveries, Inc. announces its receipt of the first in a series of pre-clinical reports from Dr. Emil Chi, chairman of the department of histopathology at the University of Washington Medical
School, for one of several studies on models of infectious diseases mimicking human infectious disease. It focused on MDI-P as a potential therapeutic agent for the treatment of sepsis. The results reaffirmed the anti-infective strength and low toxicity profile in preclinical models of MDI's patented solution, MDI-P.
The novel drug was applied to a mouse model of sepsis, to examine any
effect on this fatal bacterial infection. Sepsis is an infection of the
internal organs and generally occurs in patients during prolonged hospital
stays for surgery, pneumonia, or for treatment of wounds. This infection
carries a high risk of leading to septic shock of the internal organs and
death of the patient who has been infected. Sepsis is a leading cause of
death in intensive care units worldwide.
In this study, the goal was to test the efficacy of MDI-P in inhibiting
inflammatory responses induced in mice by the Psuedomonas aeurginosa bacterium
that frequently causes sepsis. The study used 25 percent, 50 percent and 100 percent MDI-P solutions to examine inhibition of inflammatory processes, as it is these
processes that generally lead to widespread bacterimia, followed potentially
by septic shock. MDI-P was compared against both a saline control group of
mice, as well as a positive control group of mice that had been given a
powerful antibiotic, Gentamicin, an established treatment for sepsis in
The study confirmed that the 100 percent dose strength of MDI-P offered
substantial benefit to the mice when compared both to placebo and a
50 percent survival effect comparable to Gentamicin, but without the apparent
toxicity profile that Gentamicin exhibits. All doses of MDI-P provided
substantial benefit in reducing inflammatory response of the bacterimia, but
only the 100 percent strength provided a host-sparing effect.
MDI's CEO, Judy Robinett, commented, "We are pleased
that MDI-P, our patented solution, continues to show powerful anti-infective
characteristics without associated toxicities, both in-vivo and in-vitro.
This report, in addition to other preclinical reports and our CMC/CGMP data,
will allow us to file an IND with the FDA for our initial target indication,
HIV, and enter clinical trials sometime late in 2004 or early in 2005,
continuing the path to commercialization."
Formed in 1991, Medical Discoveries, Inc. is a development-stage biopharmaceutical research company engaged in the research, development and
validation of its patented anti-infective technology.
Source: Medical Discoveries, Inc.